“We can regulate any gene, anywhere,” says CEO Dr. Amber Salzman, whose Epicrispr team is pioneering epigenetic editing - a precise, non-cutting approach - to transform neuromuscular disease treatment through durable, targeted control of gene activity.
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
"We’re hunting for the twelve entrepreneurs that will save the world - the 12 instigators,” Khosla Ventures' Rajesh Swaminathan highlights the firm’s disciplined focus on breakthrough founders and bold science.
